Mistral Pharma Inc.

Mistral Pharma Inc.

February 20, 2007 08:05 ET

Mistral Pharma Announces Positive Results from a Pilot PK Study on MIST-B02

MONTREAL, QUEBEC--(CCNMatthews - Feb. 20, 2007) - Mistral Pharma Inc. (TSX VENTURE:MIP) ("Mistral") today announced positive results from a first pilot pharmacokinetic (PK) study on its MIST-B02 product. The results of this pilot study clearly show that MIST-B02 presents a pharmacokinetic profile leading to a more interesting and simpler dosing schedule compared to the immediate-release formulation presently on the market.

"We are very excited by these positive results on MIST-B02" commented Bertrand Bolduc. "We will immediately begin presenting this opportunity to potential specialty pharmaceutical partners to pursue the development of the product" he added.

Mistral's second product, MIST-B02, is a controlled-delivery branded product in the gastroenterology field. MIST-B02 is targeting a brand product with more than US$ 100 M in worldwide annual sales.

About Mistral Pharma Inc.

Mistral Pharma is a pharmaceutical product development and drug delivery company and its first two branded products, MIST-B01 & B02, showed positive results at their respective first pilot clinical trials. Mistral is also working on other control-delivery branded products. Mistral positions itself as a development partner for specialty pharmaceutical companies. Additional information about Mistral Pharma can be obtained on Mistral Pharma's website at www.mistralpharma.com

Forward-looking Statements

Except for historical information provided herein, this press release may contain information and statements of a forward-looking nature concerning the future performance of Mistral Pharma. These statements are based on assumptions and uncertainties as well as on Management's best possible evaluation of future events. Such factors may include, without excluding other considerations, fluctuations in quarterly results, evolution in customer demand for Mistral Pharma's products, the impact of price pressures exerted by competitors, results from clinical studies and regulatory approval process as well as general market trends or economic changes. As a result, readers are advised that actual results may differ from expected results.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.

Contact Information

  • Mistral Pharma Inc.
    Bertrand F. Bolduc, B.Pharm., MBA
    President & Chief Executive Officer
    514-421-1717 # 2224
    Mistral Pharma Inc.
    Alain Provencher, CA
    Vice-president, Finance & Chief Financial Officer
    514-421-1717 # 2222